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Abstract
Background: The pathogenesis of insulin resistance in the absence of obesity is unknown. In obesity, multiple stress kinases
have been identified that impair the insulin signaling pathway via serine phosphorylation of key second messenger
proteins. These stress kinases are activated through various mechanisms related to lipid oversupply locally in insulin target
tissues and in various adipose depots.
Methodology/Principal Findings: To explore whether specific stress kinases that have been implicated in the insulin
resistance of obesity are potentially contributing to insulin resistance in non-obese individuals, twenty healthy, non-obese,
normoglycemic subjects identified as insulin sensitive or resistant were studied. Vastus lateralis muscle biopsies obtained
during euglycemic, hyperinsulinemic clamp were evaluated for insulin signaling and for activation of stress kinase pathways.
Total and regional adipose stores and intramyocellular lipids (IMCL) were assessed by DXA, MRI and 1H-MRS. In muscle of
resistant subjects, phosphorylation of JNK was increased (1.3660.23 vs. 0.7860.10 OD units, P,0.05), while there was no
evidence for activation of p38 MAPK or IKKb. IRS-1 serine phosphorylation was increased (1.3060.09 vs. 0.2260.03 OD units,
P,0.005) while insulin-stimulated tyrosine phosphorylation decreased (10.9760.95 vs. 0.8960.50 OD units, P,0.005). IMCL
levels were twice as high in insulin resistant subjects (3.2660.48 vs. 1.5860.35% H2O peak, P,0.05), who also displayed
increased total fat and abdominal fat when compared to insulin sensitive controls.
Conclusions: This is the first report demonstrating that insulin resistance in non-obese, normoglycemic subjects is
associated with activation of the JNK pathway related to increased IMCL and higher total body and abdominal adipose
stores. While JNK activation is consistent with a primary impact of muscle lipid accumulation on metabolic stress, further
work is necessary to determine the relative contributions of the various mediators of impaired insulin signaling in this
population.
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Introduction
Skeletal muscle insulin resistance contributes to the develop-
ment of type 2 diabetes mellitus (T2D) and plays a causal role in
cardiovascular disease and related disorders [1,2]. The mecha-
nisms underlying cellular resistance to insulin, however, remain
unclear. Adiposity has a strong negative impact on insulin action
in skeletal muscle [3–5], so much of the work exploring the
mechanisms of insulin resistance have employed human and
animal models of obesity. Results from these various studies
indicate that impairments in insulin signaling are mediated in
insulin target tissues by stress kinases such as c-Jun NH2-terminal
kinase (JNK), p38 mitogen-activated protein kinase (MAPK), and
inhibitor of NF-kB kinase complex beta (IKKb). These kinases
phosphorylate several key, negative regulatory, serine residues on
the insulin receptor (IR) and IRS-1 molecules, most notably
serine312 of IRS-1 (for reviews see [6,7]), resulting in the
diminished activity of enzymes in the phosphatidylinositol 3-
kinase (PI3K)/Akt pathway observed in insulin resistant tissues
[8,9].
These kinases represent multiple cross-reactive cellular stress-
response pathways that can be activated either as a result of local
factors induced by the accumulation and/or metabolism of
intracellular lipids, or by circulating adipose-secreted cytokines
such as tumor necrosis factor-alpha (TNF-a) [10–12]. This
activation of multiple stress kinases in response to an over-
accumulation of lipids describes a generalized inflammatory state
that, in obesity, has contributions from both an expansion of
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whole body adipose depots and a related cellular stress response
resulting from the deposition of ectopic lipids within muscle cells
[13,14].
Insulin resistance also occurs in lean individuals, however, and the
mechanisms contributing to impaired insulin signaling in the absence
of obesity are much less well characterized. In a study of a specific
population of insulin resistant, non-obese subjects, an increased serine
phosphorylation of IRS-1 on multiple negative regulatory sites was
observed in muscle biopsies from first degree off spring of parents with
type 2 diabetes mellitus [15]. While these data suggest that stress
kinases are involved in that population, no specific serine kinases have
been implicated in insulin resistance in the absence of obesity.
Furthermore, whether the inflammatory responses to lipid
accumulation are the ultimate cause of impaired insulin signaling
in non-obese subjects is unknown. It has been reported that, even
in subjects of normal body weight, insulin resistance is associated
with greater whole body fat stores as well as higher levels of muscle
lipids [16]. However, the total amount of adipose tissue as well as
the intramyocellular lipid stores are much smaller in healthy non-
obese than in obese individuals [17], making it unclear whether
the range at which these variables occur in an otherwise healthy,
non-obese population reach a putative threshold required to
induce a stress response in insulin target tissues. The relationship
of adiposity or insulin action to circulating levels of adipose-
secreted inflammatory cytokines, such as TNF-a, have not been
well studied in the absence of obesity. Thus, it is not clear whether
a relatively small expansion of adipose tissue in overall lean
individuals can transmit an adiposity signal to insulin target tissues
[11–14]. Similarly, a correlation between elevated intramyocel-
lular lipids (IMCL) with decreased insulin action has been
demonstrated in non-obese subjects [17–19], but it has not been
demonstrated that IMCL accumulation in this population is
associated with activation of any stress pathways.
To identify specific stress kinase pathways that might be
associated with impaired insulin signaling in the absence of
obesity, and to determine the impact of lipid accumulation on
these cellular signaling events, we have studied stress kinase
activation in skeletal muscle biopsies from in non-obese, insulin
resistant and insulin sensitive subjects with normal glucose
tolerance, and quantified total and visceral fat stores, and IMCL
content. These studies present the first evidence for activation of
the JNK stress kinase pathway in muscle from insulin resistant,
non-obese subjects, and demonstrate a corresponding increase in
IRS-1 serine phosphorylation with diminished insulin signaling.
Results
Clinical Characteristics
Subject characteristics are shown in Table 1. Twenty sub-
jects were segregated based on high or low glucose disposal values
during the hyperinsulinemic clamp (.12.0 or ,9.5 mg21?min21?
kgLBM
21?SSI21, respectively). BMI values were not significantly
different between insulin sensitive (SEN) and insulin resistant (RES)
groups. Likewise, fasting serum non-esterified fatty acids (NEFA)
and maximal aerobic capacity, measured as VO2max normalized to
kg LBM, were not significantly different between groups. Consistent
with our previous study in of the cohort from which these subjects
were recruited [20], there were no significant differences in serum
lipids or other circulating markers of cardiovascular risk between
subjects segregated for insulin sensitivity (data not shown).
Skeletal Muscle Stress Kinase Activation
Stress kinases previously demonstrated to negatively influence
insulin signaling in obesity were studied for their relationship to
insulin action in the non-obese population. We assessed the
phosphorylation state of key enzymes involved in the JNK, NF-kB,
and p38MAPK pathways in muscle biopsy samples obtained at the
time of the glucose clamp procedure prior to insulin infusion.
Activation of the JNK pathway was assessed by quantifying
phosphorylation of JNK proteins on Thr183/Tyr185 by Western
blot and normalizing these values to total JNK content.
Phosphorylation of the 55 kD JNK isoform was significantly
increased in muscle biopsies from the RES subjects (Figure 1A),
while the 46 kD band, was not consistently observable, and
therefore not quantified. Conversely, there was no significant
difference in activation of the related kinase p38 MAPK between
the RES and SEN groups, as assessed by phosphorylation of the
regulatory Thr180/Tyr182 residues normalized to total p38 MAPK
(Figure 1B). There were also no significant differences between
groups in the total content of either JNK or p38 MAPK stress
kinases (data not shown).
In order to assess activation of the NF-kB system, we measured
both the phosphorylation of the activating serine kinase IKKb and
the content of the regulatory subunit IkB that is degraded
following phosphorylation by IKKb. There were no differences in
either IKKb phosphorylation or content (Figure 1C) between
SEN and RES groups. The content of IkB was slightly, but not
statistically, lower in the RES group (0.7060.07 vs. 1.0260.14
O.D. units, RES vs. SEN, respectively, P=0.07). In the RES
subjects, however, there were also significant reductions in the
total content of both NF-kB p50 (0.5160.04 vs. 0.7860.10 O.D.
units, RES vs. SEN, respectively, P,0.05) and p65 (0.2260.06 vs.
0.4660.09 O.D. units, RES vs. SEN, respectively, P,0.05)
subunits. These observations suggest a general reduction in the
protein components of the NF-kB system in muscle from the RES
subjects, rather than an increased IKKb-mediated degradation of
IkB that would release NF-kB p50 and p65 subunits for nuclear
translocation and subsequent activation of transcription.
Skeletal Muscle Insulin Signaling
In order to determine if impairments in the insulin signal
transduction pathway consistent with JNK mediated serine
phosphorylation of IRS-1 were present in muscle from RES
subjects, we studied insulin signaling in muscle biopsy samples
under insulin-stimulated conditions. In these biopsies, obtained
after insulin infusion during the glucose clamp procedure, we
quantified IRS-1 serine and tyrosine phosphorylation and as well
as the activation state of insulin signaling intermediates upstream
and downstream of IRS-1.
Table 1. Clinical characteristics.
Insulin Sensitive
(N=10)
Insulin Resistant
(N=10)
M/I (mg21?min21?kgLBM
21?SSI21) 15.460.6 7.560.6*
ISI 16.663.2 8.061.7*
Sex (male/female) 5/5 3/7
Age (years) 3661 3461*
BMI (kg/m2) 22.661.0 24.360.6
VO2max (ml/min/kgLBM) 58.161.5 53.262.9
Serum NEFA (mmol/L) 5306108 546651
Family History of T2D 1 3
Values shown are mean 6S.E.M.
*P,0.05, RES vs. SEN groups.
doi:10.1371/journal.pone.0019878.t001
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Figure 1. JNK activation in muscle from insulin resistant, non-obese subjects accompanies reduced insulin signaling and enhanced
phosphorylation of IRS-1 on Serine312. Solubilized muscle biopsies obtained prior to insulin infusion were subject to SDS-PAGE, followed by
Western blotting with phospho-specific antibodies against JNK Thr183/Tyr185 (A), p38 MAPK Thr180/Tyr182 (B), and IKKb Ser177 (C). The predominant
band (55 kD) recognized by the anti-JNK antibody is shown and was used for quantification. Optical density values were normalized to the content
values for each protein as determined by Western blots for JNK, p38 MAPK and IKKb, and are presented as mean 6 SEM of the ratios of phospho- to
total protein. *P,0.05 RES vs. SEN groups. (D) Muscle biopsies obtained after 2 hours of insulin infusion were solubilized and assayed for
phosphorylation state of key second messengers of insulin signal transduction. Phosphorylation of Akt on Thr308 was determined by specific ELISA
JNK Activation with IMCL in Insulin Resistance
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We assessed both muscle IR content and IR tyrosine
phosphorylation by ELISA. There was a trend toward reduced
IR content in RES subjects that did not reach statistical
significance (6.360.9 vs. 10.161.8 ng/mg, P=0.07). However,
tyrosine phosphorylation per IR was not different between groups
(0.206.03 vs. 0.1560.02 O.D. units, RES vs. SEN, respectively,
P=N.S.), consistent with impaired insulin action resulting from
post-receptor mechanisms.
Downstream of the IR, however, reduced activation of insulin
signaling intermediates were observed in the RES groups. Serine
phosphorylation of Akt, a specific mediator of mediating insulin-
stimulated glucose uptake, on the regulatory Thr308 residue was
assessed by ELISA as a marker for Akt enzyme activation. We
observed that insulin-stimulated phosphorylation of Akt was
significantly lower in muscle biopsies from the RES compared to
SEN subjects (Figure 1D).
Due to the requirements for substantial amounts of muscle
protein for the immunoprecipitation procedures, we were able to
assess IRS-1 phosphorylation state in only a subset of samples (4
SEN, 3 RES) for which adequate muscle protein was available. In
these 7 samples (4 SEN, 3 RES), immunopurified IRS-1 was
obtained and assessed for tyrosine and serine phosphorylation state
by Western blot to assess whether elevated JNK activity in muscle
from the RES group would be associated with corresponding
alterations in IRS-1 phosphorylation state. In biopsies obtained
following the 2 hour insulin infusion, phosphorylation of IRS-1 on
SER312 was significantly increased in the resistant subjects
(Figure 1E). This increase in serine phosphorylation was
accompanied by a dramatic decrease in tyrosine phosphorylation
of IRS-1 (Figure 1F). Total IRS-1 protein content, as measured
by ELISA, was not different between SEN and RES groups
(109614 vs. 93620 O.D. units, RES vs. SEN, respectively,
P=N.S.).
Intramyocellular Lipid Stores
Results from in vitro studies, and studies of obese animals,
indicate that activation of JNK and other stress kinases can result
from either local lipid deposition within insulin target tissues, or as
a result of circulating cytokines, such as TNF-a, that are released
in greater quantities from expanded adipose depots. In order to
determine if increased intramuscular lipid deposition or expanded
whole body or abdominal adipose depots might be possible
contributors to the increased muscle JNK activity, we first
quantified IMCL by 1H-MRS in soleus and tibialis anterior (TA)
muscles. IMCL content was two-fold higher in RES than SEN
groups in both soleus (Figure 2A) and TA (0.7860.10 vs.
0.4060.07, respectively, P,0.01).
Total and Abdominal Fat Stores
Although there were no significant differences in BMI between
groups, we assessed whether total or abdominal fat stores might be
increased in the RES subjects by DXA and MRI. We observed
that body adipose stores were significantly increased in the RES
compared to the SEN group. DXA analysis revealed that the RES
group had higher percentages of total body fat (33.061.9 vs.
23.362.2 percent, P,0.05) and truncal fat (33.162.5 vs. 24.762.7
percent, P,0.05). Because body fat stores vary significantly
between men and women, we examined the differences in body
and normalized to total Akt content, also determined by ELISA. Values shown are mean 6 SEM. *P,0.05, RES vs. SEN groups. Lysate volumes from
insulin-stimulated muscle biopsies (4 SEN, 3 RES subjects) containing equivalent amounts of IRS-1 protein (as determined by ELISA) were
immunoprecipitated with an antibody against IRS-1. Following SDS-PAGE, Western blotting was performed with a phospho-specific antibody against
IRS-1 Ser312 (E), or with an anti-phosphotyrosine antibody (F). Blots were quantified by scanning densitometry and results expressed as mean6 SEM.
*P,0.0005, RES vs. SEN groups.
doi:10.1371/journal.pone.0019878.g001
Figure 2. Intramyocellular lipid content and body fat stores are increased in insulin resistant, non-obese subjects. IMCL content of
soleus muscles determined by 3D 1H-MRS multiple voxel technique and expressed as percent H2O peak (A). Values for percent body fat as
determined by DXA are plotted separately males and females to show the independence of gender on the relationship between adipose stores and
insulin action (B). Insulin sensitive (black bars) and resistant (white bars) groups are segregated based on results from hyperinsulinemic, euglycemic
clamp as described. Values shown are mean 6 SEM. *P,0.05, RES vs. SEN groups.
doi:10.1371/journal.pone.0019878.g002
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fat across the SEN and RES groups for men and women
separately. Body fat stores varied more as a function of insulin
sensitivity than gender (Figure 2B). Thus, the data regarding the
association between adiposity and insulin action in the present
study were not influenced by a higher percentage of females
comprising the insulin resistant group.
We then quantified abdominal fat deposits both subcutaneously
and within the abdominal cavity by MRI. MR images sufficient
for precise discrimination of fat depots were obtained for all RES
subjects, but for only 8 of 10 SEN subjects (2 males, 6 females).
Consistent with the data obtained by DXA, MRI derived values
for total abdominal fat tended to be higher in RES subjects. Total
subcutaneous adipose tissue (SAT) content of the abdomen was
50% greater in the RES than the SEN group (252634 vs.
170625 cm2), although these differences failed to reach statistical
significance (P=0.07). There was no difference in the relative
proportion of total subcutaneous adipose tissue comprising the
deep subcutaneous (DSAT) rather than the superficial sub-
cutaneous (SSAT) abdominal compartments (DSAT/SAT
ratio = 0.5060.02 vs. 0.5060.03, respectively, P=N.S.). The
amount of visceral adipose tissue (VAT) was not significantly
different between the SEN and RES groups as a whole (48.564.0
vs. 64.8611.4 cm2, SEN vs. RES, respectively, P=0.20). The
modest, non-significant differences between groups was attribut-
able entirely to higher VAT content in RES men vs. SEN men
(54.865.6 vs. 114.360.7 cm2, SEN vs. RES, respectively, P,0.05),
while there was no difference in VAT between SEN women and
RES women (42.363.9 vs. 43.665.4 cm2, SEN vs. RES,
respectively, P,0.05).
Serum TNF-a
We assessed the possibility that the expanded fat depots in RES
subjects resulted in an increase in inflammatory cytokines as is
observed in obese individuals, by measuring circulating levels of
TNF-a. Serum TNF-a was correlated with both total fat mass
(r = 0.466, P,0.05) and VAT (r = 0.564, P,0.05). Multiple
regression analysis indicated that VAT was a stronger correlate
of serum TNF-a, although the relationship between VAT and
TNF-a independent of fat mass did not reach statistical
significance (P= 0.07). However, TNF-a levels were not signifi-
cantly greater in the RES than the SEN group overall (1.5660.24
vs. 1.0260.16 pg/ml, respectively, P=0.09). While neither
variable was related to insulin sensitivity across groups, circulating
TNF-a levels across all subjects were significantly correlated with
the phosphorylation state of IKKb (r = 0.51, P,0.05).
Skeletal Muscle Mitochondrial Content
We examined the possibility that the increased IMCL content in
the RES group was associated with decreased muscle oxidative
capacity by employing a Western blot for the enzyme succinate
dehydrogenase (SDH) as a marker for muscle mitochondrial
content. There was no difference in skeletal muscle SDH content
between SEN and RES groups (1.5960.10 vs. 1.5960.07 OD
units, SEN vs. RES, respectively, P=N.S.).
Discussion
In the present study, we observed that insulin resistance in
healthy, non-obese, non-diabetic subjects was accompanied by an
increased activation of the JNK pathway with a corresponding
increase in IRS-1 serine phosphorylation in skeletal muscle tissue,
the site responsible for the majority of insulin-mediated glucose
disposal [3]. These indices of stress kinase activation were
accompanied by reduced post-receptor activation of the insulin
signaling pathway at the level of IRS-1 and Akt. Consistent with a
possible causal role of lipids in JNK activation, we observed
increased levels of intramyocellular lipids, and higher total and
abdominal adipose stores in the insulin resistant subjects, despite
their normal body weight.
Our principal findings were activation of JNK and dramatic
increase in phosphorylation of IRS-1 on SER312 in the insulin
resistant non-obese subjects. JNK has previously been implicated
only in obesity-mediated insulin resistance [21–23]. Increased
serine phosphorylation of IRS-1 has been demonstrated in insulin
resistant, non-obese subjects previously, but only in a carefully
selected population of first degree offspring of diabetic parents
[15]. In those studies, however, no specific serine kinase was
implicated. While our data do not allow us to rule out the
contribution of other cellular serine kinases on the altered
phosphorylation state of muscle IRS-1, it is highly plausible that
JNK can serve as a causal mechanism for insulin resistance in this
population.
We observed that the intracellular triglyceride content of soleus
and tibialis anterior muscles were twice as high in the insulin
resistant group in our study, indicating the potential for lipotoxic
effects in muscle cells of these subjects. When this condition is
modeled in cultured hepatocytes by incubation with saturated fatty
acids, a direct activation of the JNK pathway and serine
phosphorylation of IRS-1 results [24,25]. JNK activation in this
model is directly attributable, at least in part, to oxidative stress
resulting from increased lipid oxidation [25]. Thus, a large
component of the toxic impact of cellular lipids may occur as a
result of the burden of high rates of lipid oxidation on
mitochondria, due to the increased generation of reactive oxygen
species [26], which, in addition to activating JNK, may also impact
insulin signaling via the p38MAPK and NF-kB pathways [27]. We
could not, however, find any evidence for p38MAPK or NF-kB
activation in the present study. The influence of oxidative stress on
insulin signaling is likely complex, however, and is not yet fully
understood. It is known that angiotensin II can both contribute to
oxidative stress-induced insulin resistance [28], and directly result
in serine phosphorylation of IRS-1 [29], but the specific kinases
involved and the role of this hormone on human models of insulin
resistance have yet to be determined. Beyond oxidative stress, high
rates of lipid oxidation can also lead to incomplete lipid oxidation,
with a resultant accumulation of b-oxidation intermediates [30].
These b-oxidation intermediates, such as acyl-CoAs or acyl-
carnitines, have been linked to insulin resistance [30,31], although
their potential impact on insulin signaling is unclear.
It was not possible to determine the amount of lipid oxidation
occurring in muscle, or to assess markers for oxidative or ER stress
in the present study, although assessing these parameters along
with additional components of JNK signaling will be important
avenues for subsequent studies. Therefore, we can not conclude
whether serine kinase activation is associated with the process of
metabolizing excess lipids, or as a result of a direct effect of
intracellular lipids intermediates on stress kinase pathways. Protein
kinase C (PKC) enzymes, for example, can be directly activated by
lipid intermediates such as long chain fatty acyl-CoAs, diacylgly-
cerols, and ceramides [32] are associated with insulin resistance in
humans [33]. While the MRS technique we employed quantifies
the relatively benign triglyceride component of the intracellular
lipid pool, IMCL measures have been used as surrogate indices of
these intermediates. Due to constraints in sample size, we were
unable to determine the amount of distinct lipid intermediate
species or to assess activity of PKC enzymes. Further work will be
needed to explore the potential role for PKC activation in this
population.
JNK Activation with IMCL in Insulin Resistance
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It can not be ruled out that JNK activation in this population
also results from the effects of increased lipid stores in adipose
depots throughout the body. JNK can be activated via receptors
for adipose-derived cytokines such as TNF-a and IL-1 [25,34],
and cytokines such as these have been implicated in translating the
negative effects of expanded adipose stores into impaired insulin
signaling in muscle. Insulin resistant subjects in the present study
had significantly increased total fat stores and greater fat volume in
the abdominal region. Still, the total amount of adipose tissue in
these subjects is significantly less than that observed in obese
subjects, making it unclear whether a negative impact of adiposity
on muscle insulin action can be observed at this range of adiposity.
There are little data to suggest that potential adipokine mediators
of muscle insulin resistance are increased in non-obese subjects. In
the present study we found some evidence that, even in this
absence of obesity, increased fat stores have the potential to
produce a detrimental effect on muscle insulin action.
Circulating levels of TNF-a are increased in obese states.
Although the difference in serum TNF-a between the RES and
SEN groups did not reach statistical significance, serum TNF-a was
correlated both with total fat and visceral fat across subjects. While
TNF-a can produce activation of the JNK pathway, it has been
demonstrated that disruption of insulin signaling in cultured muscle
cells by TNF-a is mediated by p38 MAPK [35]. Neither activation
of p38 MAPK, nor the TNF-a sensitive IKKb were observed in our
resistant subjects when compared to the sensitive subjects. Thus,
circulating TNF-a is not likely to constitute a primary determinant
of JNK activity and insulin signaling in this non-obese population.
The correlations between TNF-a and adiposity, as well as muscle
IKKb, suggest that even in non-obese subjects, small increases in
total and visceral fat mass, although relatively small compared to
values for obese subjects, are still sufficient to produce increased
circulating levels of TNF-a. The lack of an association between
these variables and insulin action suggest that a threshold may be
required for TNF-a to activate the NF-kB and other pathways
sufficiently to negatively influence insulin signaling, and that this
threshold is not readily met in non-obese subjects.
The roles of other potential adipose-derived cytokines in this
population remain to be determined, and can not be excluded as
contributors to JNK activation or insulin resistance in this
population. Likewise, non-adipose derived inflammatory factors
could contribute to muscle stress kinase activation. Homocysteine
has been identified as an activator of JNK [36]. However,
homocysteine levels were not different between these groups, and
have been shown to not associate with insulin resistance in this
non-obese population [20].
While the causes of JNK activation and impaired insulin
signaling in this population remain uncertain, it is clear that the
insulin resistant subjects in our study represent a less dramatic
version of an obese phenotype with an overabundance of adipose
and muscle lipid storage, and elevated muscle JNK activation. An
obese phenotype in non-obese subjects with metabolic disturbanc-
es has been described previously [16,37]. These data, as with our
data on serum lipids and cardiovascular risk in this same
population [20], suggests that the threshold at which lipid
deposition may impact metabolic health may be relatively low,
and well within the range of what would be considered healthy
weights. Our finding of increased IMCL levels in the insulin
resistant subjects is also is in agreement with other reports
demonstrating in association of increased IMCL levels with insulin
resistance in non-obese populations [17–19,38,39], suggesting that
this local accumulation of lipids in muscle is an important
component of the development of insulin resistance in the absence
of overall obesity.
It has been suggested, based on studies of first degree offspring
of diabetic patients, that IMCL accumulation occurs in lean
subjects as a result of impaired mitochondrial content and capacity
[15,40]. In contrast to studies in that unique population [15], we
found no evidence for a reduced mitochondrial content as assessed
by SDH, suggesting a substantial difference between these
populations. While SDH content is a very crude estimate of
mitochondrial content, the variables employed in the present study
to measure total, abdominal and visceral fat, as well as IMCL
values, were all correlated across subjects, as has previously been
observed for subjects with lower total fat stores [17]. Our data is
therefore suggestive of an accumulation of fat across multiple
depots and tissue beds driving a phenotype similar to obesity,
rather than a mechanism promoting tissue-specific lipid deposi-
tion, that results in insulin resistance. Whether the accumulation of
lipids that does occur in muscle provides a disproportionate
negative impact on insulin signaling in cells of that tissue, as
compared to other fat stores, remains to be determined. Further
studies are required to determine whether reduced mitochondrial
content is indeed a significant contributor to muscle lipid
accumulation and insulin resistance, and whether the first degree
offspring of diabetic parents present with a unique phenotype
across the spectrum of insulin resistance. The present study
included a subgroup of subjects with a parental history of diabetes.
While the possibility exists that this introduced heterogeneity into
the determinants of insulin resistance, our study was designed to
assess mechanisms of insulin resistance in the general population,
which includes subjects both with and without the potential for
genetic influences on insulin resistance.
Although some studies of non-obese subjects have employed a
BMI of 25 as the cutoff point for normal weight, our results were
not influenced by the inclusion of subjects with BMI values up to
27. When only the data from those individuals with BMI values
#25 were analyzed, the results were identical; insulin resistance
was associated with increased JNK activation reduced insulin
signaling, and elevated intramyocellular lipids, abdominal and
visceral fat. Likewise, there was no difference in the trends of the
data when men and women were analyzed separately, except for
the trend for insulin resistant men to have higher amounts of
visceral fat than insulin sensitive men, a trend not observed for
women. However, the sample size involved precludes drawing any
conclusions from these data, and further studies would be required
to assess any gender differences in visceral fat accumulation, or the
potential for visceral fat depots to influence insulin action in this
population.
The group analysis aspect of the study design facilitated the
identification of characteristics that differentiated insulin resistant
from insulin sensitive subjects in an otherwise healthy population.
Pre-screening for insulin-mediated glucose disposal with subse-
quent enrollment of only the most insulin sensitive and resistant
subjects allowed for in depth study of a sufficient number of
subjects with substantial insulin resistance, considering that there is
no accepted clinical threshold to identify insulin resistance. This
design did not, however, allow us to run uni- and multivariate
analyses in an attempt to identify independent determinants of
insulin resistance of JNK activation. Further cross sectional studies
are needed to segregate the various contributors to JNK activation
and insulin resistance in this population.
In summary, we observed that insulin resistance in the non-
obese population is associated with an activation of the JNK
pathway with increased serine phosphorylation of IRS-1. Impli-
cated in this disruption of cellular insulin action is the
accumulation of lipids within skeletal muscle, and the greater
degree of overall adiposity that was observed in the insulin
JNK Activation with IMCL in Insulin Resistance
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19878
resistant subjects. Additional work is required to study additional
stress kinase pathways in greater depth, and to assess the extent
that these factors individually contribute to insulin resistance
across the non-obese population.
Materials and Methods
Subjects
Non-obese, healthy subjects between the ages of 20 and 50 were
recruited from the local population. A body mass index (BMI)
cutoff of less than 27 (25 for Asian Americans [41]) was chosen due
to the wide range of insulin sensitivity values with no correlation to
BMI reported for this population [42]. Women were premeno-
pausal. Individuals with diabetes, cardiovascular diseases, HIV
and other active infections, thyroid disorders, epilepsy, cancer,
hepatitis, cystic fibrosis, sickle cell disease, asthma or renal disease
were excluded. Subjects taking any medications known to affect
insulin sensitivity, carbohydrate metabolism, or lipid metabolism
were excluded. Exercise and general physical activity pattern were
determined using the questionnaire developed by Baecke et al
[43]. This questionnaire generates a physical-activity index score
from 3 to 15 based on work, sport and leisure time energy
expenditure, with each category scored from 1 to 5 (lowest to
highest activity level). Subjects with scores greater than 10
(population mean approximately 8.3) were not enrolled in the
study.
Ethical considerations
All subjects gave informed, written consent. The protocols and
consent forms were approved by the University of California, San
Francisco institutional review board and Clinical Research Center
where the study was conducted.
Identification of insulin sensitive and insulin resistant
subjects
The subjects participating in this study were part of a larger
cohort of subjects meeting the above entry criteria that were
employed in a study of the impact of adiposity and insulin
resistance on serum lipids and cardiovascular risk in the non-obese
population [20]. As such, data on multiple aspects of cardiometa-
bolic health in the population a larger group of non-obese
individuals that included these subjects has been presented
elsewhere. As a result of excluding individuals with BMI.27
and those with impaired glucose tolerance or fasting hyperglyce-
mia, the pool of subjects did not include any individuals meeting
the criteria for the metabolic syndrome.
Insulin sensitivity index (ISI) values determined as part of the
larger study were employed as the first of a two-step screening
process to identify insulin sensitive and resistant subjects for
enrollment in the present study. ISI values were calculated from a
75 g oral glucose tolerance test (OGTT) according to the
formula by Matsuda and DeFronzo [ISI = 10,000/!(fasting
glucose 6 fasting insulin) 6 (mean glucose 6 mean insulin)]
[44]. Subjects with impaired glucose tolerance or impaired fasting
glucose were excluded.
Qualifying subjects with high or low ISI values (greater than 13
or less than 9) were invited to participate in further screening by
hyperinsulinemic euglycemic clamp [45]. Glucose disposal values
(M/I) were calculated as mg glucose infused per min per kg lean
body mass divided by steady state insulin levels (in mU/ml6100)
between 90 and 120 minutes of the 2 hr clamp (insulin infusion
rate 80 mU/m2?min body surface area). M/I values from 39
subjects were divided into tertiles, and the values dividing the
middle tertile from the lower and upper tertiles were taken as cut
points to determine eligibility for enrollment in insulin resistant
(,9.5) and insulin sensitive (.12.0) groups for subsequent studies.
Groups were not matched for sex, but subsequent separate
analyses of group differences across sexes indicated that, except
where noted, the presence of more females in the insulin resistant
group (7 of 10) than the sensitive group (5 of 10) did not influence
the overall group differences.
Blood Chemistry
Glucose was determined in whole blood by the glucose oxidase
technique (Sigma). Insulin levels were measured by ELISA
(Millipore, Billerica, MA). Serum non-esterified fatty acids were
measured using Wako Diagnostics kit (Richmond Virginia) and
serum TNF-a were measured using the Quantikine HS high
sensitivity ELISA (R & D Systems, Minneapolis, MN) following
manufactures instructions.
Total and abdominal adipose tissue assessment
Body composition was assessed by dual-energy X-ray absorp-
tiometry (DXA). Visceral (VAT) and subcutaneous (SAT)
abdominal adipose tissue areas as well as deep subcutaneous
abdominal adipose tissue (DSAT), and superficial subcutaneous
abdominal adipose tissue (SSAT) were assessed by magnetic
resonance imaging acquired with a GE Excite 3-T scanner as
previously described [46]. Acquisition was prescribed from a
sagittal scout so that the image plane passed through the center of
the vertebral disc between vertebrae L4 and L5, and calculated
using a customized software program written in the interactive
data language platform (IDL Research Systems, Inc., Boulder,
CO) [47].
Intramyocellular lipids by 1H-MRS
As described previously [46], muscle spectral and image data
were acquired from calf muscles using a quadrature knee coil.
Single voxel Point Resolved Spectral Selection (PRESS) technique
was used to obtain spectra from tibialis anterior (TA) muscle
compartment due to size limitation of the muscle compartment,
while a 3D multi voxel technique was used to obtain spectra from
soleus muscle. Each slice was measured three times and the
average value was taken as previously described [48].
Muscle Biopsies
At time of the euglycemic hyperinsulinemic clamp, percutane-
ous muscle biopsies were obtained from the belly of the vastus
lateralis both prior to and after 120 minutes of insulin infusion
(prior to conclusion of the infusion protocol) on opposite legs.
After local anesthesia, a 5 mm diameter Bergstrom needle was
passed through a 7 mm skin incision and subcutaneous tissue,
and then advanced approximately 2 cm beyond the muscle
fascia. The biopsy (50–100 mg tissue) was obtained with applied
suction. The incision was closed with steri-strips and firm
pressure applied.
Sample Preparation
Biopsy specimens (50–100 mg wet weight) were frozen in liquid
nitrogen, pulverized and homogenized in 50 mM HEPES,
pH 7.4, 1% Triton X-100, 100 mM NaF, 10 mM Na4P2O7,
1 mM PMSF, 2 mM Na3VO4, 2 mM leupeptin, 20 mg/ml apro-
tinin. Homogenates were centrifuged at 100,0006g for 60 minutes
and lysates discarded. The pelleted samples were then solubilized
for 1 hr at 4uC and then centrifuged at 100,0006g for 60 min at
4uC, and stored at 280uC. Protein was measured by the Bradford
Assay (Pierce Chemicals).
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Immunoprecipitation/Immunoblotting
Content and phosphorylation of IR were measured by ELISA
[49]. Content of IRS-1, total AKT/PKB and serine phosphory-
lated AKT/PKB were each measured by ELISA (Cell Signaling
Technologies). Content and activation state of JNK, IKKb, and
p38 MAPK enzymes were determined by Western blots
employing antibodies to measure total and phosphorylated
proteins (Cell Signaling). Values for protein phosphorylation were
normalized to total protein content to determine the activation
state of individual kinases. Muscle GAPDH and SDH were also
quantified by Western blot (AbCam Inc). To measure IRS-1
phosphorylation, identical amounts of IRS-1 for each sample
tested were first immunoprecipitated by anti-IRS-1 antibody
(Millipore Corp) and then subjected to Western blot analyses with
either anti-phosphotyrosine (anti-PY99, Santa Cruz Biotechnolo-
gies) or anti-phosphoserine IRS-1 Serine312 (Millipore Corp)
antibodies.
Statistical analysis
Statistics were calculated using MedCalc statistical software
(MedCalc Software, Mariakerke, Belgium). Differences between
insulin sensitive and resistant groups were analyzed by Student’s t-
test. Correlations between variables were determined by Pearson
correlation coefficients. Significance was set at p,0.05. All data
are presented as mean 6 SEM.
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